Brainsway Ltd. (BWAY)

NASDAQ: BWAY · IEX Real-Time Price · USD
5.03
+0.20 (4.22%)
Jul 1, 2022 10:07 AM EDT - Market open

Company Description

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally.

It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Brainsway Ltd.
Brainsway Logo
Country United States
Founded 2003
IPO Date Apr 17, 2019
Industry Health Care Equipment & Supplies
Sector Health Care
Employees 118

Contact Details

Address:
Bynet Building
Jerusalem 9777518
Israel
Phone 972 2 582 4030

Stock Details

Ticker Symbol BWAY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $11.00
CIK Code 0001076643
CUSIP Number 10501L106
ISIN Number US10501L1061
Employer ID 04-3285165
SIC Code 3841

Key Executives

Name Position
Dr. Christopher R. von Jako Ph.D. President and Chief Executive Officer
Richard Scott Areglado Senior Vice President and Chief Financial Officer
Hadar Levy Senior Vice President and Chief Operating Officer
Christopher J. Boyer Ph.D. Vice President of Global Marketing
Avner Hagai Founder and Independent Vice-Chairman
Prof. Abraham Zangen Co-Founder, Member of Scientific Advisory Board and Director
Dr. Yiftach Roth Ph.D. Chief Scientist
Menachem C. Klein Esq. Vice President, General Counsel and Corporate Secretary
Dr. Joachim Seidel Ph.D. Vice President of Corporate Development and Strategy
Dr. Aron Tendler Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 12, 2013 REVOKED Commission order revoking Exchange Act registration [Section 12(j)]
Sep 10, 2001 4 Statement of changes in beneficial ownership of securities
Sep 5, 2001 8-K Current report
Sep 5, 2001 SC 13D/A General statement of acquisition of beneficial ownership
Sep 5, 2001 SC 13D/A General statement of acquisition of beneficial ownership
Aug 15, 2001 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 8, 2001 SC 13D/A General statement of acquisition of beneficial ownership
Aug 8, 2001 4 Statement of changes in beneficial ownership of securities
Jul 5, 2001 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Jun 27, 2001 8-K Current report